Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Adverse reactions; First in man
- Sponsors Valneva
- 19 Mar 2018 Positive interim results for the primary and secondary endpoints including safety and immunogenicity data up to Day 84 (month 3) presented in the Valneva media release.
- 18 Mar 2018 According to a Valneva media release, final safety and immunogenicity data including one year follow-up are expected early 2019.
- 24 Jul 2017 According to a Valneva media release, the company expects to announce first results from the study in the first quarter of 2018.